Stocktoria

Cullinan Therapeutics, Inc. CGEM

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-01-08

Cullinan Therapeutics, Inc. statistics & valuation

Market cap$1.1B
P / B2.8×
Return on equity-53.8%
Return on capital-58.8%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202020212022202320242025
Operating margin (%)
-358.70% 202020212022202320242025
Return on equity (%)
-25.90% -15.40% 20.80% -33.70% -28.40% -53.80% 202020212022202320242025
Shares outstanding
29.8M 44.3M 46.6M 42.9M 58.5M 60.2M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-24.10% -15.00% 19.80% -31.60% -26.90% -49.00% 202020212022202320242025
Free cash flow margin (%)
-229.30% 202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$1.52 $2.38 -$3.69 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin————-358.7%—
Net margin————-346.1%—
FCF margin————-229.3%—
Return on assets-49.0%-26.9%-31.6%19.8%-15.0%-24.1%
Return on equity-53.8%-28.4%-33.7%20.8%-15.4%-25.9%
Current ratio10.2513.5317.0721.0925.2514.82

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.